Moving towards disease modification in inflammatory bowel disease therapy

被引:69
作者
Allen, Patrick B. [1 ]
Peyrin-Biroulet, Laurent [2 ,3 ]
机构
[1] Ulster Hosp, SE Trust, Dept Gastroenterol, Belfast, Antrim, North Ireland
[2] INSERM, U954, Vandoeuvre Les Nancy, France
[3] Univ Hosp Nancy, Dept Hepatogastroenterol, Vandoeuvre Les Nancy, France
关键词
deep remission; poor prognostic indicators in IBD; treat beyond symptoms; ADALIMUMAB-TREATED PATIENTS; CROHNS-DISEASE; ULCERATIVE-COLITIS; REMISSION RATES; RISK-FACTORS; RHEUMATOID-ARTHRITIS; DOSE INTENSIFICATION; COMPLICATED DISEASE; HUMANIZED ANTIBODY; PROGRESSION;
D O I
10.1097/MOG.0b013e3283622914
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of reviewThe inflammatory bowel diseases (IBDs) are chronic disabling conditions. Despite the benefits of anti-tumor necrosis factor (TNF)- agents in improving quality of life and reducing the need for surgeries, overall only one-third of patients are in clinical remission at 1 year and loss of response is frequent. It seems clear that treatment must go beyond alleviation of symptoms in IBD. It is important that treatment targets in IBD will ensure mucosal healing and deep remission. Recent findingsThe induction of deep remission might be the best way to alter the natural course of these diseases by preventing disability and bowel damage. New disability indices and the new Crohn's disease damage score have recently been developed and they can be used to evaluate the long-term effect on patients and as new endpoints in trials. Early intervention with disease-modifying anti-IBD drugs (DMAIDs) should be considered in patients with poor prognostic factors. SummaryNew therapeutic targets in IBD patients who failed anti-TNF- therapy are urgently required, and tofacitinib, vedolizumab and ustekinumab appear to be the most promising drugs. Herein, we review the new and current trends in IBD therapy, with the final aim of changing disease course and patients' lives by both improving quality of life and avoiding disability.
引用
收藏
页码:397 / 404
页数:8
相关论文
共 63 条
[1]   Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease [J].
Abreu, MT ;
Taylor, KD ;
Lin, YC ;
Hang, T ;
Gaiennie, J ;
Landers, CJ ;
Vasiliauskas, EA ;
Kam, LY ;
Rojany, M ;
Papadakis, KA ;
Rotter, JI ;
Targan, SR ;
Yang, HY .
GASTROENTEROLOGY, 2002, 123 (03) :679-688
[2]   The molecular classification of the clinical manifestations of Crohn's disease [J].
Ahmad, T ;
Armuzzi, A ;
Bunce, M ;
Mulcahy-Hawes, K ;
Marshall, SE ;
Orchard, TR ;
Crawshaw, J ;
Large, O ;
De Silva, A ;
Cook, JT ;
Barnardo, M ;
Cullen, S ;
Welsh, KI ;
Jewell, DP .
GASTROENTEROLOGY, 2002, 122 (04) :854-866
[3]   Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease [J].
Allen, P. B. ;
Kamm, M. A. ;
Peyrin-Biroulet, L. ;
Studd, C. ;
Mc Dowell, C. ;
Allen, B. C. M. ;
Connell, W. R. ;
De Cruz, P. P. ;
Bell, S. J. ;
Elliot, R. P. ;
Brown, S. ;
Desmond, P. V. ;
Lemann, M. ;
Colombel, J-F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (04) :438-444
[4]   Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype [J].
Arnott, IDR ;
Landers, CJ ;
Nimmo, EJ ;
Drummond, HE ;
Smith, BKR ;
Targan, SR ;
Satsangi, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (12) :2376-2384
[5]   Risk factors for surgery and postoperative recurrence in Crohn's disease [J].
Bernell, O ;
Lapidus, A ;
Hellers, G .
ANNALS OF SURGERY, 2000, 231 (01) :38-45
[6]   Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review [J].
Billioud, Vincent ;
Sandborn, William J. ;
Peyrin-Biroulet, Laurent .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) :674-684
[7]   Surgery for adult Crohn's disease: what is the actual risk? [J].
Bouguen, Guillaume ;
Peyrin-Biroulet, Laurent .
GUT, 2011, 60 (09) :1178-1181
[8]   Impact of inflammatory bowel disease on health-related quality of life [J].
Casellas, F ;
López-Vivancos, J ;
Vergara, M ;
Malagelada, JR .
DIGESTIVE DISEASES, 1999, 17 (04) :208-218
[9]   Optimizing Thiopurine Therapy in Inflammatory Bowel Disease [J].
Chevaux, Jean-Baptiste ;
Peyrin-Biroulet, Laurent ;
Sparrow, Miles P. .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (06) :1428-1435
[10]  
Cleynen I., 2012, Gut